
|Articles|July 16, 2008
York Pharma raises £28 million to fund acquisitions
Milton Keynes, England - York Pharma has raised £28 million to fund a multi-million pound acquisition of Flammazine and Flammacerium from Solvay, according to BusinessWeekly.co.uk.
Advertisement
Milton Keynes, England
- York Pharma has raised £28 million to fund a multi-million pound acquisition of Flammazine and Flammacerium from Solvay, according to BusinessWeekly.co.uk.
York Pharma has agreed to to terms for a £24.2 million for debt financing and another £3.9 million raised as it takes on global commercial rights and current sales of Flammazine and Flammacerium.
Flammazine and Flammacerium are dermatologic brands for the prevention and treatment of infections in burn wounds and topical wound infections.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
CSU With Biochemical C1 Inhibitor Deficiency: Case Report Raises Diagnostic Questions
2
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
3
Common Mistakes in Managing Hair Loss and Pigmentary Disorders
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5











